SCHEMBL419729

SCHEMBL419729

B(Oc1cccc2cnccc12)Oc1cccc2cnccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA3 P22001 1/20 0.53
LMNA P02545 2/20 0.52
KDM4E B2RXH2 2/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
MAPKAPK2 P49137 1/20 0.52
HTT P42858 2/20 0.47
ALDH1A1 P00352 2/20 0.43
MAPT P10636 2/20 0.43
NSD2 O96028 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CACNA2D1 P54289 9/20 0.40
BRAF P15056 1/20 0.40
ROCK2 O75116 1/20 0.40
ROCK1 Q13464 1/20 0.40
IKBKE Q14164 1/20 0.39
TBK1 Q9UHD2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL96459 0.79 MAPT (0.58) KCNA3LMNAKDM4ECYP1A2CYP3A4
SCHEMBL96458 0.79 KCNA3 (0.54) KCNA3LMNAKDM4ECYP1A2CYP3A4
SCHEMBL1119427 0.77 PRKCZ (0.41) KCNA3KDM4ECYP1A2CYP3A4CYP2D6
SCHEMBL3994903 0.76 KCNA3 (0.51) KCNA3LMNAKDM4ECYP1A2CYP3A4
SCHEMBL215803 0.76 HTR1B (0.48) KCNA3KDM4ECYP1A2CYP2C19ALDH1A1
SCHEMBL21178262 0.75 KCNA3 (0.50) KCNA3LMNAKDM4ECYP1A2CYP3A4
SCHEMBL94801 0.75 KCNA3 (0.61) KCNA3LMNAKDM4ECYP1A2CYP3A4
SCHEMBL11144866 0.75 KCNA3 (0.61) KCNA3LMNAKDM4ECYP1A2CYP3A4
SCHEMBL21917569 0.75 CACNA2D1 (0.50) KCNA3LMNAKDM4ECYP1A2CYP3A4
SCHEMBL18356037 0.75 KCNA3 (0.50) KCNA3LMNAKDM4ECYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025027560-A1 NEW RHOJ/CDC42 INHIBITORS DEVELOPED FOR THE TREATMENT OF CANCER, BENIGN TUMORS, RETINAL DISORDERS, VASCULAR DISORDERS, AND CARDIOMYOPATHIES FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2025-02-06 WO disclosed
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO LTD (JP) 2014-10-02 US disclosed
US-8785473-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2014-07-22 US disclosed
EP-2607348-A2 Plasminogen Activator Inhibitor-1 Inhibitor Renascience CO., LTD. (JP) 2013-06-26 EP disclosed
EP-2415755-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Renascience CO., LTD. (JP) 2012-02-08 EP disclosed
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE CO., LTD. (JP) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 KCNA3 4485/4885LMNA 482/4885KDM4E 4490/4885
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 KCNA3 4485/4885LMNA 482/4885KDM4E 4490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.